Catechol-O-methyltransferase rs4680 and rs4818 haplotype association with treatment response to olanzapine in patients with schizophrenia.

Tytuł:: Catechol-O-methyltransferase rs4680 and rs4818 haplotype association with treatment response to olanzapine in patients with schizophrenia.
Autorzy:: Nikolac Perkovic M; Division of Molecular Medicine, Rudjer Boskovic Institute, Bijenicka 54, 10000, Zagreb, Croatia.
Sagud M; University Hospital Center Zagreb, Kispaticeva 12, 10000, Zagreb, Croatia.; School of Medicine, University of Zagreb, Salata 3, 10000, Zagreb, Croatia.
Zivkovic M; University Hospital Center Zagreb, Kispaticeva 12, 10000, Zagreb, Croatia.
Uzun S; Department of General Psychiatry, University Psychiatric Hospital Vrapce, Bolnicka cesta 32, 10000, Zagreb, Croatia.; Faculty of Medicine, Josip Juraj Strossmayer University, Josipa Huttlera 4, 31000, Osijek, Croatia.
Nedic Erjavec G; Division of Molecular Medicine, Rudjer Boskovic Institute, Bijenicka 54, 10000, Zagreb, Croatia.
Kozumplik O; Department of General Psychiatry, University Psychiatric Hospital Vrapce, Bolnicka cesta 32, 10000, Zagreb, Croatia.; Faculty of Medicine, Josip Juraj Strossmayer University, Josipa Huttlera 4, 31000, Osijek, Croatia.
Svob Strac D; Division of Molecular Medicine, Rudjer Boskovic Institute, Bijenicka 54, 10000, Zagreb, Croatia.
Mimica N; School of Medicine, University of Zagreb, Salata 3, 10000, Zagreb, Croatia.; Department of General Psychiatry, University Psychiatric Hospital Vrapce, Bolnicka cesta 32, 10000, Zagreb, Croatia.
Mihaljevic Peles A; University Hospital Center Zagreb, Kispaticeva 12, 10000, Zagreb, Croatia.; School of Medicine, University of Zagreb, Salata 3, 10000, Zagreb, Croatia.
Pivac N; Division of Molecular Medicine, Rudjer Boskovic Institute, Bijenicka 54, 10000, Zagreb, Croatia. .
Źródło:: Scientific reports [Sci Rep] 2020 Jun 22; Vol. 10 (1), pp. 10049. Date of Electronic Publication: 2020 Jun 22.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
Język:: English
Imprint Name(s):: Original Publication: London : Nature Publishing Group, copyright 2011-
MeSH Terms:: Polymorphism, Single Nucleotide*
Antipsychotic Agents/*administration & dosage
Catechol O-Methyltransferase/*genetics
Olanzapine/*administration & dosage
Schizophrenia/*drug therapy
Adult ; Aged ; Antipsychotic Agents/therapeutic use ; Female ; Haplotypes ; Humans ; Male ; Middle Aged ; Olanzapine/therapeutic use ; Pharmacogenomic Variants ; Schizophrenia/genetics ; Treatment Outcome ; Young Adult
References:: Huang, E. et al. Catechol-O-methyltransferase Val158Met polymorphism and clinical response to antipsychotic treatment in schizophrenia and schizo-affective disorder patients: a meta-analysis. Int. J. Neuropsychopharmacol. 19, pyv132 (2016).
Lotta, T. et al. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 34, 4202–4210 (1995). (PMID: 10.1021/bi00013a008)
Scanlon, P. D., Raymond, F. A. & Weinshilboum, R. M. Catechol-O-methyltransferase: thermolabile enzyme in erythrocytes of subjects homozygous for allele for low activity. Science 203, 63–65 (1979). (PMID: 10.1126/science.758679)
Tunbridge, E. M. et al. Which dopamine polymorphisms are functional? Systematic review and meta-analysis of COMT, DAT, DBH, DDC, DRD1-5, MAOA, MAOB, TH, VMAT1, and VMAT2. Biol. Psychiatry 86, 608–620 (2019). (PMID: 10.1016/j.biopsych.2019.05.014)
Roussos, P., Giakoumaki, S. G., Pavlakis, S. & Bitsios, P. Planning, decision-making and the COMT rs4818 polymorphism in healthy males. Neuropsychologia 46, 757–763 (2008). (PMID: 10.1016/j.neuropsychologia.2007.10.009)
Yoshida, K. & Müller, D. J. Pharmacogenetics of antipsychotic drug treatment: update and clinical implications. Mol. Neuropsychiatry 1–26, doi: 10.1159/000492332 (2018).
Sagud, M. et al. Haplotypic and Genotypic Association of Catechol-O-Methyltransferase rs4680 and rs4818 Polymorphisms and Treatment Resistance in Schizophrenia. Front. Pharmacol. 9, 705 (2018). (PMID: 10.3389/fphar.2018.00705)
Terzic, T., Kastelic, M., Dolžan, V. & Plesničar, B. K. Genetic polymorphisms in dopaminergic system and treatment-resistant schizophrenia. Psychiatr. Danub. 28, 127–131 (2016). (PMID: 27287786)
Zivkovic, M. et al. The lack of association between COMT rs4680 polymorphism and symptomatic remission to olanzapine monotherapy in male schizophrenic patients: a longitudinal study. Psychiatry Res. 279, 389–390 (2019). (PMID: 10.1016/j.psychres.2019.04.028)
Sagud, M. et al. Catechol-O-methyl transferase and schizophrenia. Psychiatr. Danub. 22, 270–274 (2010). (PMID: 20562760)
Gupta, M. et al. Association studies of catechol-O-methyltransferase (COMT) gene with schizophrenia and response to antipsychotic treatment. Pharmacogenomics 10, 385–397 (2009). (PMID: 10.2217/14622416.10.3.385)
Illi, A. et al. Interaction between angiotensin-converting enzyme and catechol-O-methyltranferase genotypes in schizophrenics with poor response to conventional neuroleptics. Eur. Neuropsychopharmacol. 13, 147–151 (2003). (PMID: 10.1016/S0924-977X(02)00176-1)
Illi, A. et al. Catechol-O-methyltransferase val108/158met genotype and response to antipsychotic medication in schizophrenia. Hum. Psychopharmacol. 22, 211–215 (2007). (PMID: 10.1002/hup.841)
Inada, T., Nakamura, A. & Iijima, Y. Relationship between catechol-O-methyltransferase polymorphism and treatment-resistant schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 120B, 35–39 (2003).
Tybura, P. et al. Pharmacogenetics of adverse events in schizophrenia treatment: Comparison study of ziprasidone, olanzapine and perazine. Psychiatry Res. 219, 261–267 (2014). (PMID: 10.1016/j.psychres.2014.05.039)
Vehof, J. et al. Clinical response to antipsychotic drug treatment: association study of polymorphisms in six candidate genes. Eur. Neuropsychopharmacol. 22, 625–631 (2012). (PMID: 10.1016/j.euroneuro.2012.01.006)
Kocabas, N. A. et al. The impact of catechol-O-methyltransferase SNPs and haplotypes on treatment response phenotypes in major depressive disorder: a case–control association study. Int. Clin. Psychopharmacol. 25, 218–227 (2010). (PMID: 10.1097/YIC.0b013e328338b884)
Andreasen, N. C. et al. Remission in schizophrenia: proposed criteria and rationale for consensus. Am. J. Psychiat. 162, 441–449 (2005). (PMID: 10.1176/appi.ajp.162.3.441)
Leucht, S., Davis, J. M., Engel, R. R., Kissling, W. & Kane, J. M. Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. Acta Psychiatr. Scand. 119, 7–14 (2009). (PMID: 10.1111/j.1600-0447.2008.01308.x)
Molero, P., Ortuño, F., Zalacain, M. & Patiño-García, A. Clinical involvement of catechol-O-methyltransferase polymorphisms in schizophrenia spectrum disorders: influence on the severity of psychotic symptoms and on the response to neuroleptic treatment. Pharmacogenomics J. 7, 418–426 (2007). (PMID: 10.1038/sj.tpj.6500441)
Stefanis, N. C. et al. Variation in catechol-o-methyltransferase val158 met genotype associated with schizotypy but not cognition: a population study in 543 young men. Biol. Psychiatry 56, 510–515 (2004). (PMID: 10.1016/j.biopsych.2004.06.038)
Bertolino, A. et al. COMT Val158Met polymorphism predicts negative symptoms response to treatment with olanzapine in schizophrenia. Schizophr. Res. 95, 253–255 (2007). (PMID: 10.1016/j.schres.2007.06.014)
Anttila, S. et al. Interaction between NOTCH4 and catechol-O-methyltransferase genotypes in schizophrenia patients with poor response to typical neuroleptics. Pharmacogenetics 14, 303–307 (2004). (PMID: 10.1097/00008571-200405000-00005)
Fijal, B. A. et al. Candidate-gene association analysis of response to risperidone in African American and white patients with schizophrenia. Pharmacogenomics J. 9, 311–318 (2009). (PMID: 10.1038/tpj.2009.24)
Weickert, T. W. et al. Catechol-O-methyltransferase val108/158met genotype predicts working memory response to antipsychotic medications. Biol. Psychiatry 56, 677–682 (2004). (PMID: 10.1016/j.biopsych.2004.08.012)
Woodward, N. D., Jayathilake, K. & Meltzer, H. Y. COMT val108/158met genotype, cognitive function, and cognitive improvement with clozapine in schizophrenia. Schizophr. Res. 90, 86–96 (2007). (PMID: 10.1016/j.schres.2006.10.002)
Zhao, Q. Z. et al. Association between a COMT polymorphism and clinical response to risperidone treatment: a pharmacogenetic study. Psychiatr. Genet. 22, 298–299 (2012). (PMID: 10.1097/YPG.0b013e328358629a)
Kaneko, H. et al. COMT Val 108/158 Met polymorphism and treatment response to aripiprazole in patients with acute schizophrenia. Neuropsychiatr. Dis. Treat. 14, 1657–1663 (2018). (PMID: 10.2147/NDT.S164647)
Bosia, M. et al. COMT Val158Met and 5-HT1A-R –1019 C/G polymorphisms: effects on the negative symptom response to clozapine. Pharmacogenomics 16, 35–44 (2015). (PMID: 10.2217/pgs.14.150)
Escamilla, R. et al. Association study between COMT, DRD2, and DRD3 gene variants and antipsychotic treatment response in Mexican patients with schizophrenia. Neuropsychiatr. Dis. Treat. 14, 2981–2987 (2018). (PMID: 10.2147/NDT.S176455)
Gong, Y. et al. Polymorphisms in microRNA target sites influence susceptibility to schizophrenia by altering the binding of miRNAs to their targets. Eur. Neuropsychopharmacol. 23, 1182–1189 (2013). (PMID: 10.1016/j.euroneuro.2012.12.002)
Nackley, A. G. et al. Human catechol-O-methyltransferase haplotypes modulate protein expression by altering mRNA secondary structure. Science 314, 1930–1933 (2006). (PMID: 10.1126/science.1131262)
Rajagopal, V. M., Rajkumar, A. P., Jacob, K. S. & Jacob, M. Gene-gene interaction between DRD4 and COMT modulates clinical response to clozapine in treatment-resistant schizophrenia. Pharmacogenet. Genomics 28, 31–35 (2018). (PMID: 10.1097/FPC.0000000000000314)
Johnson, E. C. et al. No evidence that schizophrenia candidate genes are more associated with schizophrenia than non-candidate genes. Biol Psychiatry. 82, 702–708 (2017). (PMID: 10.1016/j.biopsych.2017.06.033)
Sherva, R. & Farrer, L. A. Power and pitfalls of the genome-wide association study approach to identify genes for Alzheimer’s disease. Curr. Psychiatry. Rep. 13, 138–146 (2011). (PMID: 10.1007/s11920-011-0184-4)
Brandl, E. J., Kennedy, J. L. & Müller, D. J. Pharmacogenetics of antipsychotics. Can. J. Psychiatry 59, 76–88 (2014).
Nikolac Perkovic, M. et al. Association between the brain-derived neurotrophic factor Val66Met polymorphism and therapeutic response to olanzapine in schizophrenia patients. Psychopharmacology 231, 3757–3764 (2014).
First, M. B., Spitzer, R. L., Williams, J. B. W. & Gibbons, M. Structured clinical interview for DSM-IV-patient edition (SCID-P) (American Psychiatric Press, Washington, DC, 1995).
Kay, S. R., Fisbein, A. & Opler, L. A. The Positive and negative Syndrome Scale (PANSS) for schizophrenia. Schizophr. Bull. 13, 261–276 (1987). (PMID: 10.1093/schbul/13.2.261)
Miller, S. A., Dykes, D. D. & Polesky, H. F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 16, 1215 (1988). (PMID: 10.1093/nar/16.3.1215)
Rodriguez, S., Gaunt, T. R. & Day, I. N. Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am. J. Epidemiol. 169, 505–514 (2009). (PMID: 10.1093/aje/kwn359)
Barrett, J. C., Fry, B., Maller, J. & Daly, M. J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21, 263–265 (2005). (PMID: 10.1093/bioinformatics/bth457)
Purcell, S. et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 8, 559–575 (2007). (PMID: 10.1086/519795)
Faul, F., Erdfelder, E., Lang, A. G. & Buchner, A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav. Res. Methods 39, 175–191 (2007). (PMID: 10.3758/BF03193146)
Substance Nomenclature:: 0 (Antipsychotic Agents)
EC 2.1.1.6 (COMT protein, human)
EC 2.1.1.6 (Catechol O-Methyltransferase)
N7U69T4SZR (Olanzapine)
Entry Date(s):: Date Created: 20200624 Date Completed: 20201210 Latest Revision: 20210622
Update Code:: 20240105
PubMed Central ID:: PMC7308339
DOI:: 10.1038/s41598-020-67351-5
PMID:: 32572118
: Czasopismo naukowe

Pełny tekst

Antipsychotic drugs target primarily dopaminergic system which makes catechol-O-methyltransferase (COMT) an interesting target in studies searching for treatment response predictors in schizophrenia. The study assessed the association of the COMT rs4680 and rs4818 polymorphisms with therapeutic response to olanzapine, risperidone, clozapine or other antipsychotic medication after 8 weeks of monotherapy in patients with schizophrenia. 521 Caucasian patients with schizophrenia received a monotherapy with olanzapine (10-20 mg/day; N = 190), risperidone (3-6 mg/day; N = 99), or clozapine (100-500 mg/day; N = 102). The fourth group (N = 130) consisted of patients receiving haloperidol (3-15 mg/day), fluphenazine (4-25 mg/day) or quetiapine (50-800 mg/day). Treatment response was defined as a 50% reduction from the baseline positive and negative syndrome scale (PANSS) total and subscale scores, but also as an observed percentage reduction from the initial PANSS 0-6 total and subscale scores. Carriers of the COMT rs4680 A allele and carriers of the COMT rs4680-rs4818 C-A haplotype block had greater reduction in the PANSS total scores following olanzapine treatment, compared to carriers of the COMT rs4680 GG genotype and other COMT rs4680-rs4818 haplotypes. The COMT rs4680 A allele, and COMT rs4680-rs4818 C-A haplotype, were significantly associated with therapeutic response in patients treated with olanzapine, but not in patients treated with other antipsychotics.

Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Informacja